SBFM sunshinebiopharma.com Final Profit

Corporate emblem and logo of Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma (SBFM) current revenue is supported by sales of core generics while breakthrough developments are being prepared. The company's total financial result on the GURU.Markets service base chart demonstrates local dynamics, where -0.01 shows the value of this parameter. Structural flexibility is ensured by outsourcing research, while the absence of proprietary plants via the CMO model minimizes capital risks.

SBFM (Sunshine Biopharma) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Sunshine Biopharma, Inc. (SBFM)

- stock value and consensus price forecast:
Market Price sunshinebiopharma.com|SBFM - Price Target Chart
- market capitalization data:
Market Value Sunshine Biopharma, Inc.|SBFM - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Sunshine Biopharma|SBFM - Book Capitalization|Market Cap to Net Assets Ratio sunshinebiopharma.com|SBFM - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Sunshine Biopharma|SBFM - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Sunshine Biopharma Inc.|SBFM - Company Aggregate Debts|Debts to Book Value Sunshine Biopharma, Inc.|SBFM - Company Long-Term Debt|Short-Term Debt Volume Sunshine Biopharma|Quick Ratio sunshinebiopharma.com
- net income and valuation multiples indicators:
SBFM - Company Net Income
Fundamental valuation:SBFM sunshinebiopharma.com
Manufactured product of sunshinebiopharma.com

The efficiency of Sunshine Biopharma (SBFM) in developing anticancer and antiviral drugs converts directly into a net financial result after deducting all operating expenses. This metric measures the business's actual ability to generate value, allowing investors to assess the fair control premium over assets through the dynamic change in the company's profit.

Main competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Company Net Income Accuray Incorporated (ARAY)|Net Financial Result sellaslifesciences.com|Actuate Therapeutics - Net Income|Net Profit Citius Oncology Inc. CTOR|HURA - Company Net Income|TARA (Protara Tx) - Company Profit|Fate Therapeutics, Inc. (FATE) - Company Net Income|WHWK - Net Financial Result|TCRX (TScan Therapeutics Inc) - Net Profit|CSBR: Final Profit|Net Profit XBIT|Net Financial Result cel-sci.com|Company Net Income OS Therapies Incorporated OSTX|RADX: Company Profit|Artiva - Net Profit|Company Net Income Adlai Nortye Ltd.|VERU (Veru Pharma) - Net Income|Tempest Therapeutics Corp - Final Profit|XLO (Xilio Therapeutics Inc) - Net Profit|Company Net Income RENB|Net Profit MURA|Net Financial Result kairospharma.com|Company Net Income OnKure Therapeutics OKUR|CytoMed Therapeutics Ltd (GDTC) - Company Net Income|CRIS - Company Net Income|Profit After Tax APLM|THAR: Net Profit|Advanced Biomed - Final Profit|GNPX (Genprex, Inc) - Net Profit|Net Profit Calidi Bio|Company Net Income Xenetic Biosciences (XBIO)|SLRX (salariuspharma.com) - Final Profit|Company Net Income Purple Biotech Ltd. PPBT|AONC - Net Income|BeOne Medicines - Net Profit|CKPT - Net Profit|Elevation Oncology, Inc. (ELEV) - Company Net Income|ICAD - Net Financial Result|IKNA (Ikena Oncology Inc.) - Net Profit|Company Net Income NTBL|Net Profit VIRX|MOR: Profit After Tax|Company Net Income NAYA Biosciences NAYA|AAPGV - Net Income